Pharmanutra at CPHI Worldwide 2026 in Milan: a first look at what’s new for 2027

CPHI Worldwide 2026 draws to a close today at Fiera Milano, following three days in which the Group took centre stage with Sucrosomial^® Technology, its new September launches and a preview of the innovations coming in January 2027.

From 6 to 8 October, Pharmanutra attended CPHI Worldwide 2026, held at Fiera Milano.
The world’s leading international event dedicated to ingredients and technologies for the pharmaceutical industry brought together more than 62,000 professionals, over 2,900 exhibiting companies, representatives from more than 166 countries and over 250 expert speakers.
Across three days of meetings, discussion and networking, Pharmanutra shared its vision: turning scientific research into solutions that anticipate health and well-being needs.

Sucrosomial^® Technology at the heart of innovation

Once again, Sucrosomial^® Technology was at the heart of Pharmanutra’s presence at CPHI Worldwide 2026. This delivery system, conceived and patented by the Group, is designed to support nutrient absorption and tolerability.
It is a technological solution that continues to evolve, broadening its range of applications and reaffirming the role of Pharmanutra research in advancing the international nutraceutical sector.
At the stand, visitors and partners explored the latest scientific evidence and discovered how Sucrosomial^® Technology shapes products designed for different needs, age groups and lifestyles.

September’s new launches: energy and performance

Among the highlights were the new Pharmanutra supplements featuring Sucrosomial® Technology, launched on the Italian market in September: Apportal^® Master and Apportal^® Junior, developed respectively to support the well-being of people over 50 and younger age groups, together with Sucrosomial^® Creatine, a formulation designed to support athletes’ preparation and performance.
In particular, Apportal^® Master and Sucrosomial^® Creatine reflect two strategic directions in the Group’s research: on the one hand, comprehensive support for physical and mental energy at different stages of life; on the other, the application of Sucrosomial^® Technology to sports nutrition, including its innovative use with creatine.

A look ahead to Pharmanutra’s 2027 innovations

CPHI Worldwide 2026 also offered an opportunity to give international partners an exclusive preview of the new products expected in January 2027, providing a glimpse of the portfolio’s next developments and the Group’s latest research applications. This preview reinforced the value of CPHI as a place to meet and exchange ideas, build new opportunities and work with partners around the world to turn innovation into tangible projects.

Growing together with our partners

In an increasingly connected market, CPHI Milan was a strategic opportunity for Pharmanutra to strengthen relationships, establish new collaborations and share a vision of growth built on science, technology and quality. The stand served as a meeting point for exploring products, projects and future prospects, and above all for highlighting the value of an international network that is growing alongside the Group.

“Every year, CPHI marks a key milestone in the company’s growth journey. In the early editions, we attended mainly to identify new distributors and enter new markets. Today, the event is a strategic opportunity to strengthen the relationships we have built over time, discuss the business surrounding existing products and present the solutions that our R&D department will make available in the future. The interest these innovations attract is a source of great satisfaction for us. Our engagement with manufacturing partners also reflects the company’s evolution: today, we manage volumes around three times higher than five years ago, and we look ahead with growth prospects in line with the trend of recent years. CPHI is therefore no longer just a showcase, but a tangible opportunity to strengthen partnerships and lay the foundations for our next phase of international development,” says Carlo Volpi, COO and Executive Director of Pharmanutra.